Prevail Therapeutics to Present at Upcoming Investor Conferences
- Asa Abeliovich, M.D., Ph.D., Founder and Chief Executive Officer of Prevail, will participate in the Jefferies Gene Therapy/Editing Virtual Summit, including a fireside chat at
11:30 a.m. ETand a panel discussion at 3:15-3:55 p.m. ETon Thursday, October 1, 2020
- Dr. Abeliovich will present at the Chardan’s 4th Annual
Genetic Medicines Conferenceon Tuesday, October 6, 2020 at 2:00 p.m. ET.
Webcasts of the presentations will be available under "Events and Presentations" in the Investors and Media section of the Company's website at ir.prevailtherapeutics.com following the presentations.
Prevail is a gene therapy company leveraging breakthroughs in human genetics with the goal of developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The Company is developing PR001 for patients with Parkinson’s disease with GBA1 mutations (PD-GBA) and neuronopathic Gaucher disease; PR006 for patients with frontotemporal dementia with GRN mutations (FTD-GRN); and PR004 for patients with certain synucleinopathies.
Prevail was founded by Dr. Asa Abeliovich in 2017, through a collaborative effort with The Silverstein Foundation for Parkinson’s with GBA and OrbiMed, and is headquartered in New York, NY.
Forward-Looking Statements Related to Prevail
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Examples of these forward-looking statements include statements concerning the potential for Prevail’s gene therapy candidates to transform the treatment of patients with, and slow or halt the progression of, FTD-GRN and other neurodegenerative diseases. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: Prevail’s novel approach to gene therapy makes it difficult to predict the time, cost and potential success of product candidate development or regulatory approval; Prevail’s gene therapy programs may not meet safety and efficacy levels needed to support ongoing clinical development or regulatory approval; the regulatory landscape for gene therapy is rigorous, complex, uncertain and subject to change; the fact that gene therapies are novel, complex and difficult to manufacture; and risks relating to the impact on our business of the COVID-19 pandemic or similar public health crises. These and other risks are described more fully in Prevail’s filings with the
Source: Prevail Therapeutics